Caplin Point Laboratories Limited has announced a major strategic move to expand its presence in the regulated U.S. pharmaceutical market by acquiring ten approved Abbreviated New Drug Applications (ANDAs) for injectable and ophthalmic products from a leading multinational generic pharmaceuticals manufacturer. The development was disclosed through filings made to Indian stock exchanges as part of the company’s routine compliance and investor updates.
The newly acquired portfolio taps into an addressable market estimated at approximately USD 473.2 million for the 12-month period ending August 2025, underscoring the substantial commercial opportunity these products represent in the U.S. market. The move marks a significant enhancement of Caplin Point’s product offerings and accelerates its drive to bolster regulated market revenues.
According to the company’s Chairman, C.C. Paarthipan, the U.S. remains a “key growth driver” and the acquisition aligns with long-term strategic plans to strengthen Caplin Point’s therapeutic portfolio. Notably, the acquired lineup includes select oncology injectables, which the company plans to commercialize from its dedicated oncology facility at Kakkalur. This specialized focus reflects the broader strategy of combining manufacturing scale with high-value product segments.
Caplin Point’s broader expansion blueprint also extends beyond the United States, with future commercialization efforts targeted at other regulated markets such as Mexico, Canada, the European Union, and Brazil, as part of a coordinated global rollout for the acquired products.
